The First Digital International Panda Festival Opens on November 3, 2020 in Meishan, China
3.11.2020 20:00:00 EET | Business Wire | Press release
With the theme of "Panda World, World Panda--For Nature As It Is", the first digital International Panda Festival is hosted by Sichuan Forestry and Grassland Administration (Giant Panda National Park Sichuan Administration), Information Office of Sichuan Provincial People's Government, Sichuan Foreign Affairs Office, Sichuan Internet Information Office, International Union for Conservation of Nature (IUCN) China Representative Office, organized by Sichuan Digital Panda Technology Development Co., Ltd., co-organized by Sichuan Provincial People's Association for Friendship with Foreign Countries, Chengdu Research Base of Giant Panda Breeding and Sichuan Giant Panda Protection Foundation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201103005025/en/
The First Digital International Panda Festival (Photo: Business Wire)
Giant pandas are the "messenger of peace" in China's opening to the outside world. Sichuan ranks first in the area of giant panda habitat, the number of wild giant panda population and captive giant pandas in China.
Sichuan, as one of the pilot areas of the Giant Panda National Park, covers an area of 20,177 square kilometers, accounting for 74.36%. There are 1,227 giant pandas in the wild, accounting for 75.23%.
The opening ceremony launches a “space-air-ground-man” integrated digital platform. Locals will be able to learn about the life of Sichuan-based giant pandas living in foreign countries. Meanwhile, it releases books such as the Gift of Nature - Discovering Sichuan as It Is, Landscape of Bamboo forests in Sichuan, Secret Sichuan - the 88 Most Beautiful Forest and Grass Landscapes to Go. It also releases the top six lists of “the Most Beautiful Bamboo Landscape” in Chengdu-Chongqing Economic Circle, as well as the Guidelines on Promoting the Development of Natural Education by eight departments including Sichuan Provincial Forestry and Grassland Administration, Sichuan Provincial Development and Reform Commission, Education Department of Sichuan Province, etc. Besides, Forest and Grassland Fire Research Institute, Sichuan Academy of Forestry Sciences are inaugurated.
Six forums and three conferences systematically present successful experiences in building high-quality forest and grassland fire barriers. Exhibitions such as the Nature Reserve Photo Exhibition, the Giant Panda Cultural and Creative Exhibition, and the Giant Panda International Art Exhibition make you appreciate the unique charm.
The digital International Panda Festival will strive to develop into a branded network exchange platform with distinctive themes at both national and international levels, making itself the only global flagship platform with western characteristics in China.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201103005025/en/
Contact information
Media Contact
Sichuan Digital Panda Technology Development Co., Ltd.
Name: Tina Tian
Email: digitalpanda@digitalgiantpanda.com
Websites: http://www.digitalgiantpanda.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom